Rituximab for the treatment of connective tissue disease–associated interstitial lung disease: A systematic review and meta-analysis

Background: Interstitial lung disease (ILD) is a common pulmonary disease often associated with significant morbidity and mortality in patients with connective tissue diseases (CTD). Currently, no gold-standard therapies are available for CTD-ILD. Recently, several studies have proposed that rituxim...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Linrui, Wang, Faping, Luo, Fengming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650441/
https://www.ncbi.nlm.nih.gov/pubmed/36386239
http://dx.doi.org/10.3389/fphar.2022.1019915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650441/
https://www.ncbi.nlm.nih.gov/pubmed/36386239
http://dx.doi.org/10.3389/fphar.2022.1019915

Ejemplares similares